ASLAN Pharmaceuticals (ASLN)

[starbuxsux]

ASLAN Pharmaceuticals reports positive data from three dose cohorts for study of ASLAN004 for the treatment of moderate to severe atopic dermatitis

6:09 AM ET 3/1/21 | Briefing.com

Co announces positive interim unblinded data from the three dose cohorts of its ongoing randomised, double-blind placebo controlled multiple ascending dose study of ASLAN004 for the treatment of moderate to severe atopic dermatitis. ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potential as a differentiated, novel treatment for AD.The Phase 1 study evaluated three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously and is now recruiting a fourth (expansion) cohort (600mg).The average baseline Eczema Area Severity Index score of patients was 32.5 and the average Investigators Global Assessment score was 3.4.At week 8, the average reduction in EASI from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% compared to 42% for patients on placebo.Peak pruritus improved after just one dose and continued to improve by an average of 46% relative to baseline at 8 weeks compared to 16% for patients on placebo.